 Connection
Kelly Faulk to Humans
This is a "connection" page, showing publications Kelly Faulk has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.062 |
|
|
|
-
Faulk KE, Anderson-Mellies A, Cockburn M, Green AL. Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020; 15(4):e0230824.
Score: 0.020
-
Faulk KE, Sopfe JM, Campbell K, Liptzin DR, Liu AK, Franklin ARK, Cost CR. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. Br J Haematol. 2018 10; 183(2):251-256.
Score: 0.018
-
Faulk K, Gore L, Cooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Paediatr Drugs. 2014 Jun; 16(3):213-27.
Score: 0.013
-
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023 01; 37(1):61-71.
Score: 0.006
-
Rush C, Faulk KE, Bradley ZK, Turner A, Krumins M, Greenhawt M. The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience. J Allergy Clin Immunol Pract. 2022 02; 10(2):630-632.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|